An open-label trial to assess the safety of regorafenib in turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)

Dane, F.Özgürdal, K.Yalçın, S.Benekli, M.Aykan, N. F.Yücel, I.Özkan, M.Evrensel, T.Sevinç, A.Coşkun, H. S.Şanlı, U. S.Kara, I. O.2024-08-022024-08-022015-06-010923-7534https://doi.org/10.1093/annonc/mdv233.253https://hdl.handle.net/11452/43649Bu çalışma, 1-4 Temmuz 2015 tarihlerinde Barcelona'da düzenlenen ESMO 17. Dünya Gastrointestinal Kanser Kongresinde bildiri olarak sunulmuştur.enScience & technologyLife sciences & biomedicineOncologyOncologyAn open-label trial to assess the safety of regorafenib in turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)Meeting Abstract00035704740012326Supplement 410.1093/annonc/mdv233.253